Revolution Medicines (NASDAQ:RVMD) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Revolution Medicines (NASDAQ:RVMD - Free Report) in a report published on Tuesday,RTT News reports. They currently have a $73.00 target price on the stock, up from their prior target price of $67.00. Wedbush also issued estimates for Revolution Medicines' Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($3.41) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at $1.97 EPS.

A number of other analysts have also issued reports on RVMD. Needham & Company LLC reissued a "buy" rating and set a $57.00 target price on shares of Revolution Medicines in a research note on Tuesday. HC Wainwright restated a "buy" rating and issued a $72.00 target price (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Stifel Nicolaus reduced their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Oppenheimer boosted their price target on Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, Guggenheim reduced their price objective on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Revolution Medicines has an average rating of "Buy" and a consensus price target of $67.58.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD traded down $0.57 during trading hours on Tuesday, hitting $36.91. 2,709,972 shares of the company's stock traded hands, compared to its average volume of 1,631,998. Revolution Medicines has a 1 year low of $29.17 and a 1 year high of $62.40. The business has a fifty day moving average price of $39.61 and a 200-day moving average price of $40.06. The firm has a market capitalization of $6.88 billion, a P/E ratio of -9.23 and a beta of 1.10.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period in the previous year, the company earned ($0.70) earnings per share. As a group, equities analysts predict that Revolution Medicines will post -3.49 earnings per share for the current year.

Hedge Funds Weigh In On Revolution Medicines

A number of large investors have recently made changes to their positions in RVMD. Charles Schwab Investment Management Inc. grew its stake in Revolution Medicines by 9.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company's stock worth $84,467,000 after buying an additional 167,997 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Revolution Medicines by 11.4% in the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company's stock worth $186,000 after acquiring an additional 434 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Revolution Medicines by 516.0% in the first quarter. SG Americas Securities LLC now owns 18,103 shares of the company's stock worth $640,000 after acquiring an additional 15,164 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Revolution Medicines by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 88,327 shares of the company's stock worth $3,863,000 after acquiring an additional 30,155 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Revolution Medicines by 11.1% during the fourth quarter. American Century Companies Inc. now owns 641,646 shares of the company's stock valued at $28,066,000 after acquiring an additional 64,238 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.